„How do we help patients around the world?”
Our novel technological platform solution unlocks the delivery of community-based infectious disease management at scale.
As stated by the World Health Organisation (WHO) anti-microbial resistance is an increasingly serious threat to global public health that requires action across all government sectors and society. Without effective antibiotics, the success of major surgery and cancer chemotherapy would be compromised. As the development of new molecules is challenging, we need to use available molecules in the best possible way. Especially in terms of resistant microorganisms, existing oral and parenteral dosing schemes can be ineffective.
Worst case this leads to death (even in more advanced health care systems the risk of death dying from sepsis is up to 30%), but also to further spread in resistant organisms, making it a highly dangerous vicious circle.
For these reasons RevIVe develops a medical device, that allows prolonged and continuous infusion, resulting in effective and safe dosing of antibiotics. Contrary to existing infusion pumps used for the delivery of parenteral antibiotics, our device not only delivers the antibiotic solution, but also freshly prepares the solution within the device. Our innovative medical device eliminates the requirement for aseptic compounding and overcomes the problem of limited in-use stability of antibiotics for prolonged and continuous delivery.
Thanks to this revolutionary innovation, RevIVe not only simplifies and improves the safety of current hospital infusion delivery management, but also accelerates and transforms the access to outpatient parenteral antimicrobial therapy (OPAT). OPAT is a growing and necessary health care delivery system, driven by the need to reduce hospital-based costs. In addition the existing hospitalization concepts need to be changed. As hospitals are an ideal breeding ground for superbugs and patients should be transferred once stable enough as soon as possible to home-care treatment.
The current OPAT system mainly relies on elastomeric infusion pumps, suffering from following disadvantages:
- Poor stability of β-lactam antibiotics, once dissolved in liquid solutions
- Onsite, expensive and error-prone compounding
- Highly resource intensive due to frequent dosing
Hence, the existing system is not scalable and fails to provide full-scale OPAT. For convenience, physicians tend to select non-targeted antibiotics with less frequent dosing like ceftriaxone and this exacerbates the impact on the gut microbiome, increasing the risk of Clostridium difficile infection and thus propelling the emergence of drug-resistant organisms.
Our technical platform is an infusion pump, that delivers antibiotics from cassettes. The device-drug solution is easily portable, allowing routine activities. Each cassette can hold a full day’s dose therefore requires only once a day changing which involves simple replacement of the used cassette much as one would change a sony-walkman cassette. The range of antibiotics delivered in this way is essentially infinite, eliminating the need for compounding and intense nursing support. Availability at scale allows early discharge on IV-antibiotics, reducing in-patient costs, optimal use of healthcare resources, decreased risks of nosocomial infections and improved quality of life for patients.
Our medical device is not only limited to anti-infectives’ treatment, but also the ideal for the parenteral delivery of drugs which are unstable in solution.